# Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]

> **NCT07694427** · PHASE3 · NOT_YET_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 720 (estimated)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Mocertatug rezetecan
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07694427
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-09
- **Primary completion:** 2029-09-06
- **Final completion:** 2032-11-08
- **Target enrollment:** 720 (ESTIMATED)
- **Last updated:** 2026-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07694427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07694427, "Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07694427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*